Regulating the p53 pathway: in vitro hypotheses, in vivo veritas, Nature Reviews Cancer, vol.55, issue.12, pp.909-923, 2006. ,
DOI : 10.1002/gcc.20310
Blinded by the Light: The Growing Complexity of p53, Cell, vol.137, issue.3, pp.413-431, 2009. ,
DOI : 10.1016/j.cell.2009.04.037
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2, Science, vol.303, issue.5659, pp.844-848, 2004. ,
DOI : 10.1126/science.1092472
Discovery of RG7388, a Potent and Selective p53???MDM2 Inhibitor in Clinical Development, Journal of Medicinal Chemistry, vol.56, issue.14, pp.5979-5983, 2013. ,
DOI : 10.1021/jm400487c
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy, Blood, vol.106, issue.9, pp.3150-3159, 2005. ,
DOI : 10.1182/blood-2005-02-0553
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study, The Lancet Oncology, vol.13, issue.11, pp.1133-1140, 2012. ,
DOI : 10.1016/S1470-2045(12)70474-6
MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models, Cancer Research, vol.73, issue.8, pp.2587-2597, 2013. ,
DOI : 10.1158/0008-5472.CAN-12-2807
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis, Experimental Hematology, vol.42, issue.2, pp.137-145, 2014. ,
DOI : 10.1016/j.exphem.2013.11.012
SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression, Cancer Research, vol.74, issue.20, pp.5855-5865, 2014. ,
DOI : 10.1158/0008-5472.CAN-14-0799
Regulation of megakaryocyte maturation and platelet formation, Journal of Thrombosis and Haemostasis, vol.113, issue.Suppl. 1, pp.227-234, 2009. ,
DOI : 10.1111/j.1538-7836.2009.03398.x
Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside, British Journal of Haematology, vol.379, issue.Suppl. 1, 2013. ,
DOI : 10.1111/bjh.12328
Endomitotic Megakaryocytes form a Midzone in Anaphase but Have a Deficiency in Cleavage Furrow Formation, Cell Cycle, vol.5, issue.5, pp.538-545, 2006. ,
DOI : 10.4161/cc.5.5.2537
Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling, Blood, vol.112, issue.8, pp.3164-3174, 2008. ,
DOI : 10.1182/blood-2008-03-144956
Presence of a defect in karyokinesis during megakaryocyte endomitosis, Cell Cycle, vol.91, issue.23, pp.4385-4389, 2012. ,
DOI : 10.1073/pnas.0610163104
Polyploidy, Experimental Hematology, vol.28, issue.1, pp.3-16, 2000. ,
DOI : 10.1016/S0301-472X(99)00124-1
Roads to polyploidy: The megakaryocyte example, Journal of Cellular Physiology, vol.16, issue.1, pp.7-20, 2002. ,
DOI : 10.1002/jcp.10035
Fundamental differences in endoreplication in mammals and Drosophila revealed by analysis of endocycling and endomitotic cells Megakaryocyte polyploidization is associated with a functional gene amplification, Proc Natl Acad Sci Blood, vol.101, pp.541-544, 2003. ,
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. The Journal of experimental medicine, pp.2017-2031, 2011. ,
In vitro senescence and apoptotic cell death of human megakaryocytes, Blood, vol.90, pp.2234-2243, 1997. ,
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition, Proceedings of the National Academy of Sciences, vol.105, issue.10, pp.3933-3938, 2008. ,
DOI : 10.1073/pnas.0708917105
The new thrombopoietic agenda: Impact on leukemias and MDS, Best Practice & Research Clinical Haematology, vol.27, issue.3-4, pp.288-292, 2014. ,
DOI : 10.1016/j.beha.2014.10.012
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP, New England Journal of Medicine, vol.355, issue.16, pp.1672-1681, 2006. ,
DOI : 10.1056/NEJMoa054626
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms, Cell Death and Disease, vol.91, issue.7, p.738, 2013. ,
DOI : 10.1016/j.dnarep.2011.07.003
Proposed megakaryocytic regulon of p53: the genes engaged to control cell cycle and apoptosis during megakaryocytic differentiation, Physiological Genomics, vol.44, issue.12, pp.638-650, 2012. ,
DOI : 10.1152/physiolgenomics.00028.2012
Role of tumor suppressor p53 in megakaryopoiesis and platelet function, Experimental Hematology, vol.40, issue.2, pp.131-142, 2012. ,
DOI : 10.1016/j.exphem.2011.10.006
Distinct roles of Mdm2 and Mdm4 in red cell production, Blood, vol.109, issue.6, pp.2630-2633, 2007. ,
DOI : 10.1182/blood-2006-03-013656
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells, Blood, vol.117, issue.9, pp.2567-2576, 2011. ,
DOI : 10.1182/blood-2010-07-295238
Deletion 5q MDS: Molecular and therapeutic implications, Best Practice & Research Clinical Haematology, vol.26, issue.4, pp.365-375, 2013. ,
DOI : 10.1016/j.beha.2013.10.013
Pathogenesis of the erythroid failure in Diamond Blackfan anaemia, British Journal of Haematology, vol.23, issue.4, pp.611-622, 2010. ,
DOI : 10.1111/j.1365-2141.2009.07993.x
Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow, Blood, vol.88, pp.1284-1296, 1996. ,
p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes, Current Biology, vol.17, issue.15, pp.1298-1307, 2007. ,
DOI : 10.1016/j.cub.2007.06.068
Proplatelet formation is regulated by the Rho/ROCK pathway, Blood, vol.109, issue.10, pp.4229-4236, 2007. ,
DOI : 10.1182/blood-2006-04-020024